The latest price target for NeoGenomics (NASDAQ:NEO) was reported by Benchmark on April 29, 2026. The analyst firm set a price target for $11.00 expecting NEO to fall to within 12 months (a possible -23.93% downside). 13 analyst firms have reported ratings in the last year.

The latest analyst rating for NeoGenomics (NASDAQ:NEO) was provided by Benchmark, and NeoGenomics upgraded their buy rating.

The last upgrade for NeoGenomics Inc happened on April 29, 2026 when Benchmark raised their price target to $11. Benchmark previously had a hold for NeoGenomics Inc.

The last downgrade for NeoGenomics Inc happened on July 29, 2025 when William Blair changed their price target from N/A to N/A for NeoGenomics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of NeoGenomics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for NeoGenomics was filed on April 29, 2026 so you should expect the next rating to be made available sometime around April 29, 2027.

While ratings are subjective and will change, the latest NeoGenomics (NEO) rating was a upgraded with a price target of $0.00 to $11.00. The current price NeoGenomics (NEO) is trading at is $14.46, which is out of the analyst’s predicted range.